Cüneyt TAYMAN, Davut BOZKAYA, Sabriye KORKUT

Evaluation of therapeutic and prophylactic platelet transfusion practices in a neonatal intensive care unit

Aim: To investigate the causes of thrombocytopenia requiring platelet transfusion (PT), clinical factors influencing the decision togive PT, and the frequency of major hemorrhage post-PT in a neonatal intensive care unit (NICU).Material and Methods: This retrospective cross-sectional study included neonates who underwent PT at least once in the NICUduring a 4-month period. Demographic characteristics, postnatal age at time of PT, number of PTs, thrombocytopenia etiology, andoccurrence of major hemorrhage were analyzed. PT threshold was 503/μL in group 3.Results: Thirty-seven (4.9%) of the 751 patients admitted to the NICU during the study period received PT. These 37 patients receiveda total of 133 PTs. The most common etiology of thrombocytopenia requiring PT was sepsis (83.5%), followed by NEC (9.8%).Of the 133 PTs, 7 were administered for early-onset thrombocytopenia and 126 for late-onset thrombocytopenia. All patients ingroup 1 (n=56) had severe thrombocytopenia only with no additional morbidity; patients in group 2 (n=72) had thrombocytopeniaaccompanied by severe morbidity and/or major hemorrhage, coagulopathy, or extremely low birth weight (ELBW); patients in group3 (n=4) received PT due to thrombocytopenia and preoperative preparation, coagulopathy, or major hemorrhage. Seven of the 133PTs (5.3%) were therapeutic and the other 126 (94.7%) were prophylactic. Existing major hemorrhage persisted after 6 of the 7therapeutic PTs. Major hemorrhage occurred after only 1 prophylactic PT.Conclusion: It was identified bacterial sepsis and NEC as the two most common clinical indications for PT. In general, prophylactic PTwas not followed by major hemorrhage, whereas recurrent major hemorrhage occurred after therapeutic PT. Therefore, randomizedcontrolled studies are needed to determine a safe PT threshold value based on a scoring system for predicting the risk of majorhemorrhage.

PDF

___

1. Christensen RD. Platelet transfusion in the neonatal intensive care unit: Benefits, risks, alternatives. Neonatology 2011;100:311-8.
2. Cremer M, Sallmon H, Kling PJ, et al. Thrombocytopenia and platelet transfusion in the neonate. Semin Fetal Neonatal Med 2016;21:10-8.
3. Sainio S, Jarvenpaa AL, Renlund Met al. Thrombocytopenia in term infants: a population-based study. Obstet Gynecol 2000;95:441-6.
4. Dreyfus M, Kaplan C, Verdy E, et al. Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group. Blood 1997;89:4402-6.
5. Castle V, Andrew M, Kelton J, et al. Frequency and mechanism of neonatal thrombocytopenia. J Pediatr 1986;108:749-55.
6. Mehta P, Vasa R, Neumann L, et al. Thrombocytopenia in the high-risk infant. J Pediatr 1980;97:791-4.
7. Christensen RD, Henry E, Wiedmeier SE, et al. Thrombocytopenia among extremely low birth weight neonates: data from a multihospital healthcare system. J Perinatol 2006;26:348-53.
8. Del Vecchio A, Sola MC, Theriaque DW, et al. Platelet transfusions in the neonatal intensive care unit:factors predicting which patients will require multiple transfusions. Transfusion 2001;41:803-8.
9. Del Veccio A, Motta M. Evidence based platelet transfusion recommendations in neonates. J Matern Fetal Neonatal Med 2011;24:38-40.
10. Stanworth SJ, Clarke P, Watts T, et al. Propsective, observational study of outcomes in infants with severe thrombocytopenia. Pediatrics 2009;124:826-34.
11. Venkatesh V, Khan R, Curley A, et al. How we decide when a neonate needs transfusion. Br J Haematol 2013;160:421- 33.
12. Christensen RD. Platelet transfusion in the neonatal intensive care unit: benefits, risks, alternatives. Neonatology 2011;100:311-18.
13. Perk Y, Atasay B, Çetinkaya M. Turkish Society of Neonatology Blood Products Transfusion Guideline-2016. www.neonatology.org.tr/tnd-tani-ve-tedavi-protokolleri erişim tarihi 2016.
14. Roberts I, Murray NA. Neonatal thrombocytopenia. Semin Fetal Neonatal Med 2008;13:256-64.
15. Sola-Visner M, Saxonhouse MA, Brown RE. Neonatal thrombocytopenia: what we do and don’t know. Early Hum Dev 2008;84:499-506.
16. Kling PJ, Hutter JJ. Hematologic abnormalities in severe neonatal necrotizing enterocolitis: 25 years later. J Perinatol 2003;23:523-30.
17. Roberts I, Murray NA. Neonatal thrombocytopenia: causes and management. Archs Dis Childh Fetal Neonatal Ed 2003;88:359-64.
18. Dohner ML, Wiedmeier SE, Stoddard RA, et al. Very high users of platelet transfusions in the neonatal intensive care unit. Transfusion 2009;49:869-72.
19. Josephson CD, Su LL, Christensen RD, et al. Platelet transfusion practices among neonatologists in the United States and Canada: results of a survey. Pediatrics 2009;123:278-85.
20. Murray NA, Howarth LJ, McCloy MP, et al. Platelet transfusion in the management of severe thrombocytopenia in neonatal intensive care unit patients. Transfus Med 2002;12:35-41.
21. Gibson BE, Todd A, Roberts I, et al. Transfusion guidelines for neonates and older children. Br J Haematol 2004;124:433-53.
22. Strauss RG. How I transfuse red blood cells and platelets to infants with the anemia and thrombocytopenia of prematurity. Transfusion 2008;48:209-17.
23. Bussel J. Diagnosis and management of the fetus and neonate with alloimmune thrombocytopenia. J Thromb Haemost 2009;7:253-7.
24. New HV. Paediatric transfusion. Vox Sang 2006;90:1-9.
25. Curley A, Venkatesh V, Stanworth S, et al. Platelets for neonatal transfusion study 2: a randomised controlled trial to compare two different platelet count thresholds for prophylactic platelet transfusion to preterm neonates. Neonatology 2014;106:102-6.